Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585895 · ClinicalTrials.gov registry record · Phase 3
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT02585895 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 39 participants.
The verdict
NCT02585895, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
Interventions
- BIOLOGICAL Evolocumab
- PROCEDURE Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2017-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02585895
The ClinicalTrials.gov registry entry for NCT02585895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evolocumab is the first listed.
NCT02585895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02585895 about?
NCT02585895 is a clinical study titled "Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment". To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
What is the current status of trial NCT02585895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2015-12-21. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT02585895?
The interventions under investigation include: Evolocumab (BIOLOGICAL), Low-density Lipoprotein Cholesterol (LDL-C) Apheresis (PROCEDURE).
Who is sponsoring clinical trial NCT02585895?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.